The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
CJC-1295 + Ipamorelin — the synergistic growth hormone pulse
CJC-1295 alone has some small human PK/PD studies. Ipamorelin has limited human data. The combination specifically has no published controlled human trial.
The GH Stack produces measurable increases in GH pulse amplitude and IGF-1, which is documented. Whether those increases translate to meaningful long-term benefits in body composition, sleep quality, or longevity in otherwise healthy adults is not established. People feel better on it — sleep improvement is the most consistent report — but placebo-controlled evidence for clinical outcomes is absent.
What each compound contributes — and why it's in the stack.
CJC-1295 + Ipamorelin — GHRH analog paired with a ghrelin mimetic. CJC stimulates the pituitary to produce/release GH (GHRH receptor); Ipamorelin amplifies the pulse (GHSR receptor) without the cortisol/prolactin elevation of GHRP-2/6. Combined-chapter entry — separate CJC-1295 and Ipamorelin chapters coming soon.
Full CJC-1295 + Ipamorelin chapterCJC-1295 (without DAC) and Ipamorelin work on different receptors — GHRH-R and GHSR respectively — and their combined effect on GH pulse amplitude is synergistic, not merely additive. CJC tells the pituitary "release GH now"; Ipamorelin amplifies the ghrelin signal that makes the pituitary more responsive. Together they produce a stronger GH pulse than either alone. The pre-bed timing aligns with the body's natural GH release window, which peaks in the first few hours of sleep. Using no-DAC CJC (short-acting, ~30 min) keeps the pulse physiological rather than creating the sustained elevation from CJC-with-DAC.
This reflects how this combination is used in practice. It is not a prescribing guide and does not constitute medical advice.
| Phase | Timing | Compounds & doses | Notes |
|---|---|---|---|
| Timing | 30 min pre-bed | Both peptides injected SC simultaneously (or drawn into same syringe) | Fasted state preferred — food elevates somatostatin which blunts GH release. No food 2 hours before injection. |
| Standard cycle | 5×/week (skip weekends) or daily | CJC-1295 no-DAC 100 mcg + Ipamorelin 100–200 mcg | Some protocols skip 2 days/week to avoid desensitization of GH receptors. Others run daily. No controlled data on optimal frequency. |
| Duration | 12–20 weeks on, 4–8 weeks off | — | IGF-1 monitoring recommended on cycles >12 weeks. Target staying within physiological range. |
Adults over 30 experiencing age-related decline in GH/IGF-1 seeking improvement in sleep quality, body composition (lean mass retention, mild fat loss), and recovery. Most appropriate for people who respond poorly to lifestyle optimization alone. Not appropriate as a first intervention — sleep, training, and protein should be optimized first.
Informational only. Ranges vary significantly by vendor, vial size, and country. No pharmaceutical-grade source exists for most of these compounds; figures are not a buying guide.